Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
161 Leser
Artikel bewerten:
(0)

ITL Profit Doubles In Half Year 2016/2017 Results

MELBOURNE, Australia, Feb. 23, 2017 /PRNewswire/ -- ITL Limited, (ASX: ITD), an innovative diversified healthcare company, is pleased to announce excellent results for the half year ended 31 December 2016 compared with the previous corresponding period. A full "Results and ITL BioMedical Growth Update" presentation can be viewed here.

Highlights

  • Profit after tax of $2.12m (Dec 2015: $1.04m; up 104%)
  • Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up 83%)
  • Revenue of $17.5m (Dec 2015: $15.7m; up 11%)
  • Profit before tax of $2.12m (Dec 2015: $1.01m; up 110%)
  • EBITDA was $2.7m (Dec 2015: $1.6m; up 69%)
  • Net Debt $5.0m (June 2016: $5.5m; down 9%)

The significant increase in profit was driven by improvements in the BioMedical and Healthcare divisions.

ITL BioMedical won new customers, grew its product portfolio and benefited from improved market conditions.

ITL Healthcare achieved improved profitability from strategic sourcing and customer initiatives whilst costs have been carefully controlled.

ITL's investment in MyHealthTest, the direct to consumer pathology test provider for major chronic diseases, has focused on critical systems development and expanding the range of tests.

ITL intends to continue reducing identified key risks, drive product growth and enter new markets in order to keep driving business growth.

The Board expects a strong result for the full financial year even allowing for some seasonality in the 2nd half year.

Logo- http://mma.prnewswire.com/media/471428/ITL_Health_Group_Logo.jpg

About ITL Limited

ITL Limited (ASX:ITD) is an innovative global medical technology company that creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the blood culture testing market, estimated to be worth US$3.3bn.

ITL maintains four divisions including ITL BioMedical, ITL Healthcare, ITL Clinical and MyHealthTest. The Company holds an IP portfolio of 48 patents and sells into 55 countries, protecting healthcare workers in millions of procedures annually.

For more information or inquiries please email info@itl-limited.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.